Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66227 | 0.82 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL29151002 | 0.79 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL28509290 | 0.79 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Benzene SCHEMBL7864298 | 0.79 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL2271826 | 0.78 | GABRA1 (0.33) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL15915015 | 0.78 | LMNA (0.32) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Hydrogen Peroxide SCHEMBL10893500 | 0.77 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Hydrogen Peroxide SCHEMBL8612837 | 0.77 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| Hydrogen Peroxide SCHEMBL51044 | 0.77 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRB2LMNA | |
| SCHEMBL3378475 | 0.77 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-9970103-B2 | Film deposition material, sealing film using the same and use thereof | TOSOH CORPORATION (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160326642-A1 | FILM DEPOSITION MATERIAL, SEALING FILM USING THE SAME AND USE THEREOF | TOSOH CORPORATION (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20140219903-A1 | FILM DEPOSITION MATERIAL, SEALING FILM USING THE SAME AND USE THEREOF | TOSOH CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| US-20030187027-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2002089782-A2 | DIOXANES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-11-14 | — | — | WO | disclosed |
| US-4617413-A | Pentacoordinate silicon complexes, the process for their preparation and their application to the preparation of organosilanes | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1986-10-14 | — | — | US | disclosed |
| EP-0191260-A1 | Pentacoordinated silicon complexes, process for their preparation and their use in preparing organosilanes | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | GABRA1 4773/4885GABRG2 4863/4885GABRB3 4859/4885 |
| US-20030187027-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | GABRA1 4216/4885GABRG2 4055/4885GABRB3 4107/4885 |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | GABRA1 4773/4885GABRG2 4863/4885GABRB3 4859/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | GABRA1 4270/4885GABRG2 4064/4885GABRB3 4116/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | GABRA1 3099/4885GABRG2 4370/4885GABRB3 3904/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | GABRA1 4389/4885GABRG2 3958/4885GABRB3 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.